Company Address:
Exactech, Inc.
2320 NW 66th Ct.

Gainesville, Florida
32653
USA
Phone:
(352) 377-1140
Website:
www.exac.com
Ticker:
EXAC
Exchange:
Nasdaq
FREE E-MAIL ALERTS

  • ABOUT HAWK
  • HAWK CLIENTS
  • HAWK SERVICES
  • CONTACT HAWK
2320 NW 66th Ct. • Gainesville • Florida • 32653 • USA • www.exac.com
Investor Contact: Frank N. Hawkins, Jr. or Julie Marshall · Hawk Associates Inc. · (305) 451-1888 · www.hawkassociates.com
Exactech Enters Definitive Agreement with TPG Capital to Go Private. Leading Healthcare Investor Provides Company with Strategic Growth Capital. Shareholders to Receive $42 per Share in Cash.
ALERT: Exactech Enters Definitive Agreement with TPG Capital to Go Private. Leading Healthcare Investor Provides Company with Strategic Growth Capital. Shareholders to Receive $42 a Share in Cash. Please click the red PDF button to see a printable Investment Profile for Exactech.

Please click the Additional Information link to your left for Investor information for Exactech

Exactech is a pure play orthopaedic competitor gaining market share in the rapidly expanding global biomedical device industry. The company's products are used in the restoration of bones and joints that have deteriorated as a result of injury or disease such as arthritis.

Exactech develops, manufactures, markets, distributes and sells its orthopaedic implant devices, including knee, shoulder and hip implant systems, surgical instrumentation and biologic services to hospitals and physicians in the U.S. and over 30 markets in Europe, the Americas, Asia and the Pacific. International sales represented 31.3% of total 2016 company sales.

Founded and led by an orthopaedic surgeon, the company has built its success on its customer-centric culture. Design assistance and feedback from its surgeon customers have helped Exactech develop a pipeline of innovative products that improve patient outcomes.

Differentiators

FDA CLEARED PRODUCTS AND SERVICES



The company’s rapidly growing Equinoxe® shoulder implant system, the company’s largest segment, increased revenues in 2016 by 16% to $100.3M. The company attributes the growth of the Equinoxe system to continued surgeon success, a robust pipeline of enhancements and reduced operating room time saving thousands of dollars per case for hospitals. Shoulder sales represented 38.9% of company revenue in 2016. The company’s Vantage® Total Ankle System, an addition to the Exactech extremities product line and the first product in the foot and ankle market, was introduced in the third quarter of 2016.

Knee systems that meet the needs of hospitals and surgeons have been a hallmark of the company. Exactech’s Logic knee system and its Optetrak® differentiated, knee implant products provided 28.3% of the company's 2016 revenue.

Hip products, which accounted for 16.7% of company revenues in 2016, use materials such as ceramic bearing surfaces and enhanced polyethylene for industry leading wear performance. The most recently released Alteon® tapered wedge hip stem has been enthusiastically embraced by the company’s surgeon customers. Recent News
Exactech Announces Successful First Revision Knee Replacement Surgery with Truliant® Instrumentation
Exactech Q3 Revenue $61.4 Million
Exactech Cancels Q3 Earnings Call Previously Scheduled for Tuesday, October 31, 2017
Exactech Enters Definitive Agreement with TPG Capital to Go Private
Exactech Comments on Impact of Hurricanes Irma and Harvey. Adjusts Q3 Earnings Guidance and Announces Q3 Earnings Call

    Risk Factors
  • Market acceptance of new products
  • Significant resources of larger competitors
  • New government taxes
  • Partial dependency on third-party manufacturers
  • Foreign exchange volatility

Management
Executive Chairman-
William Petty, M.D.

CEO and Director-
David W. Petty

Executive Vice President of Finance & Chief Financial Officer-
Joel C. Phillips, CPA

Executive Vice President of Research and Development-
Gary J. Miller, Ph.D.

Vice President of Administration; Corporate Secretary-
Betty B. Petty

Senior Vice President, General Manager – Biologics Division-
Bruce Thompson

Director-
James G. Binch

Director-
Albert H Burstein, Ph.D.

Director-
William B. Locander, Ph.D.

Director-
Richard C. Smith

Director-
Fern S. Watts

Director-
W. Andrew Krusen

Back To Top